猪圆环病毒2型Cap蛋白及传染性法氏囊病病毒VP2蛋白的VLPs自组装表达与免疫效力评价

为了利用同一重组大肠杆菌实现不同种动物疫病来源类病毒样颗粒(virus like particles, VLPs)的高效组装表达,试验将编码猪圆环病毒2型(PCV2)Cap蛋白和传染性法氏囊病病毒(IBDV)VP2蛋白的核苷酸序列分别克隆至pET28a-Rcodon载体中,并分别转化至改造的BL21(DE3)△lpxM tig⁺感受态细胞中,利用纳米粒度电位仪及透射电子显微镜分析目的蛋白表达后的胞内组装情况,并用纯化后的抗原蛋白制备的疫苗免疫动物进行免疫效力评价。结果表明：PCV2 Cap蛋白和IBDV VP2蛋白的可溶性表达水平较优化前对照组均分别提高90%左右,且目的蛋白在胞内高效自组装形成了VLPs,并排列呈均一的晶格结构;含VP2抗原的亚单位疫苗可提供100%的保护效果,含PCV2抗原的亚单位疫苗的抗体水平较高,显著高于阴性对照组纯化后的抗原蛋白制备的疫苗(P<0.05)。说明PCV2 Cap蛋白和IBDV VP2蛋白在BL21(DE3)△lpxM tig⁺感受态细胞中均可实现高效可溶性表达与细胞内VLPs自组装,且免疫原性良好...     

猪圆环病毒二型Capsid表面五倍轴loops的研究进展

猪圆环病毒1型(PCV1)与猪圆环病毒2型(PCV2)的核苷酸序列高度同源,但两者的Cap蛋白结构存在较大差异且PCV1不致病。通过近年来研究两者Cap蛋白结构的文献以及比对PCV1与PCV2病毒颗粒表面五倍轴的三段loops氨基酸序列及蛋白3D结构模拟展示结果,观察Loop BC,Loop DE以及Loop HI的潜在功能和作用,本综述目的在于进一步揭示PCV2 virus-like particles(VLPs)组装及其细胞入侵分子机理,有助于PCV2疫苗及药物载体等的研究与开发,为PCV2疫苗、药物载体等研究与开发奠定理论基础。     

猪圆环病毒2型山西流行株Cap蛋白可溶性表达与免疫原性分析

为建立猪圆环病毒2型(PCV2)山西流行毒株Cap蛋白的原核可溶性表达体系,并分析比较重组蛋白与2种商品化基因工程Cap亚单位疫苗在小鼠体内不同阶段的免疫原性,本试验以PCV2e SXJX株(GenBank登录号：MH922991.1)的ORF2基因为基础,根据大肠埃希菌密码子偏性优化序列,将其插入原核表达载体pET-28a-c(+)中,鉴定为阳性后转入宿主菌BL21(DE3)中,经优化表达条件后,对超声破碎后的菌体上清进行纯化,分析纯化后产物的纯度和抗原性,并利用负染透射电镜观察重组Cap蛋白体外自组装成病毒样颗粒(VLPs)。分别将同等免疫剂量的PCV2e重组Cap蛋白和2种商品化PCV2基因工程亚单位疫苗免疫健康BALB/c雌鼠,应用ELISA方法检测不同阶段小鼠体内特异性抗体的水平。结果显示：重组Cap蛋白可在大肠埃希菌中表达,以完全可溶性形式存在于菌体超声波破碎后的上清中,表达产物纯化效果良好,并能被PCV2单克隆抗体识别;透射电镜观察结果发现,表达的重组Cap蛋白可以自组装成约20 mm大小的VLPs;动物免疫试验结果显示,在首免后第21天PCV2e Cap试验组抗体水平显...     

猪圆环病毒2型病毒样颗粒研究进展

猪圆环病毒2型(PCV2)是引起猪圆环病毒相关疾病的主要病原体,给养殖业造成重大经济损失。一直以来,对于PCV2的防控主要通过疫苗接种。目前使用的疫苗可大致分为全病毒灭活疫苗、嵌合病毒疫苗、重组亚单位疫苗三大类。病毒样颗粒(VLPs)作为一种伪病毒,以其高免疫原性、高安全性成为新型疫苗的研究热点。本文综述了VLPs在国内外的最新研究动态、研究和开发的意义,提出了VLPs作为一种基因转载工具,其研究为疫苗研发开拓了新的方向。     

新疆天康将推出三款猪用疫苗

<正>猪圆环病毒2型重组杆状病毒亚单位灭活疫苗由新疆天康畜牧生物技术股份有限公司技术中心研制的猪圆环病毒2型重组杆状病毒亚单位灭活疫苗,是应用分子生物学技术将猪圆环病毒2型Cap基因重组于杆状病毒内,在昆虫细胞上培养表达PCV2-r Cap蛋白而制成的亚单位疫苗。该疫苗与市场使用的猪圆环病毒2型全病毒灭活疫苗相比,具有极其显著的特点:(1)以当前的优势基因型毒株PCV2b基因序列做参考,经杆状病毒系统表达出类似病毒样颗粒(VLPs)的蛋白,抗原的     

猪细小病毒病毒样颗粒研究进展

猪细小病毒(PPV)是引起母猪繁殖障碍和仔猪死亡的主要病原,疫苗免疫预防是控制该病的主要手段。由于对生物安全的担心,目前国内使用的疫苗仍以灭活苗为主。病毒样颗粒(VLPs)疫苗以其安全性高、免疫原性好成为各类病毒疫苗研究的热门方向。猪细小病毒病毒样颗粒(PPV-VLPs)是不含PPV DNA的空衣壳结构,由PPV VP2结构蛋白体外自行组装形成,形态上与天然病毒粒子相似,具有很强的免疫原性和生物学活性。论文就VLPs疫苗的免疫机制及PPV-VLPs的组装及其在国内外的研究进行综述,为PPV-VLPs研究提供参考。     

猪圆环病毒2型衣壳蛋白体外表达研究现状

猪圆环病毒2型(PCV2)是引起猪圆环病毒相关疾病(PCVAD)的主要病原体,会破坏免疫系统,引起多种病毒或细菌的混合感染与继发感染,给养猪业造成了巨大经济损失。目前疫苗免疫仍然是防控PCVAD的有效手段,核衣壳蛋白(Cap)是主要免疫保护性抗原,因此Cap蛋白基因工程疫苗是研究的理想靶抗原,获得大量、可溶性、富有活性的PCV2 Cap蛋白是疫苗研制的关键因素。论文综述了利用大肠埃希氏菌、酵母菌、活病毒载体等体外表达系统表达PCV2 Cap蛋白的进展,为PCV2新型基因工程疫苗的研制提供依据。     

猪圆环病毒疫苗临床免疫效果观察

猪圆环病毒2型(PCV2)是危害世界养猪业的一个重要病原,造成巨大经济损失。本试验选用PCV2 SH毒株水包油包水乳剂及其水佐剂灭活疫苗、进口的Ingelvac~?CircoFLEX~(TM)基因工程亚单位疫苗和国产的大肠杆菌表达的重组Cap亚单位疫苗,在确诊PCV2感染的某规模化猪场开展仔猪免疫试验。结果显示:两种PCV2 SH株灭活疫苗均能明显降低发病率和死亡率,降低病毒血症,提高日增重,其免疫效果与CircoFLEX疫苗相当,优于大肠杆菌表达的重组Cap亚单位疫苗,值得推广应用。     

口蹄疫病毒病毒样颗粒研究进展

口蹄疫病毒病毒样颗粒(virus-like particles,VLPs)是不含口蹄疫病毒RNA的空衣壳结构,由口蹄疫病毒的4种结构蛋白体外自组装形成的,形态上与天然病毒粒子相似,具有很强的免疫原性和生物学活性。文章介绍了口蹄疫病毒衣壳的组装、口蹄疫病毒VLPs在国内外的研究进展和影响VLPs形成的因素,并对VLPs在疫苗研制等方面的应用前景作了展望。     

重组新城疫病毒表达猪圆环病毒2型Cap蛋白的研究

为构建表达猪圆环病毒2型(PCV2)衣壳蛋白(Cap)的重组新城疫病毒(NDV),本研究利用NDV LaSota弱毒疫苗株为活病毒载体,通过反向遗传操作系统构建出表达PCV2 Cap的重组病毒(rLa-PCV2/Cap),以及表达删除核定位信号(NLS)的Cap(Cap△41)的重组病毒(rLa-PCV2/Cap△41),并对外源蛋白的表达效果进行了检测.通过间接免疫荧光试验证明,两种重组病毒感染的BHK-21细胞中,PCV2 Cap蛋白以及删除NLS的Cap△41蛋白均获得正确表达;其中,完整的Cap蛋白定位于核内,而删除NLS的Cap△41蛋白则定位于胞浆中,本研究结果为研究新型PCV2疫苗奠定基础.     

Effect of porcine circovirus type 2 (PCV2) vaccination on PCV2-viremic piglets after experimental PCV2 challenge

The objective of this study was to evaluate the effect of porcine circovirus type 2 (PCV2) vaccines on PCV2-viremic and -seropositive piglets born from naturally PCV2-infected sows against postnatal PCV2 challenge. The experimental design was aimed at mimicking commercial swine rearing conditions to evaluate the response of the PCV2 vaccine on PCV2-viremic and -seropositive piglets after experimental PCV2 challenge. PCV2a (or 2b)-viremic piglets received a PCV2 vaccine at 21 days of age followed by a PCV2b (or 2a) challenge at 49 days of age (28 days post vaccination). The PCV2 vaccines elicited a high level of humoral (as measured by immunoperoxidase monolayer assay and neutralizing antibody titers) and cellular (as measured by the frequency of PCV2-specific interferon-γ-secreting cells) immune response in the PCV2-viremic piglets after vaccination even in the presence of maternally derived antibodies (MDA). The initial infection of PCV2 in the pigs was not affected by PCV2 vaccination, however the challenging PCV2 was reduced by PCV2 vaccination on PCV2-viremic pigs. The results from this study demonstrate that the PCV2 vaccine used in this study is effective at reducing PCV2 viremia and lymphoid PCV2 DNA, even for PCV2-viremic pigs with passively acquired MDA at the time of vaccination.     

猪圆环病毒3型与猪圆环病毒2型二重PCR检测方法的建立

为建立同时检测PCV3和PCV2的二重PCR方法,分别以PCV3和PCV2基因组的保守区域设计2对特异性引物,片段大小分别为649,295 bp。将反应条件进行优化,构建PCV3和PCV2的二重PCR检测方法。检测结果表明该方法能特异性扩增PCV3和PCV2,且无法扩增其他猪常见病毒;PCV3和PCV2的最低检出限分别为508,412 copies/μL。临床样品检测结果显示,PCV3和PCV2阳性率分别为2.1%(3/145),62.1%(90/145),PCR产物经测序证实为PCV3。本研究建立的二重PCR方法具有速度快、特异性强和灵敏度等优点,可以用于PCV3和PCV2的检测和流行病学调查。     

Detection of porcine Circovirus type 2 (PCV2) variants PCV2-1 and PCV2-2 in Brazilian pig population

In the present study whole genome of six Brazilian isolates of PCV2 were sequenced, analyzed and compared with 35 other sequences (24 from other countries and 17 from Brazil). The phylogenetic analysis showed that mostly Brazilian variants of PCV2 were grouped as PCV2-1. Two isolates among the six analyzed here could not be grouped with any other PCV2-2 analyzed in this study. One of these isolates was from an aborted fetus with myocarditis and the other from a PMWS affected pig. The results pointed here showed that both groups of PCV2 are present in Brazilian pig population without any clear geographical correlation.     

Establishment and Rudimentary Application of the nano-dPCR for Detection of PCV2 and PCV3

This study was aimed to establish a duplex nanoparticle-assisted PCR (nano-dPCR) method for the simultaneous detection of porcine circovirus type 2 (PCV2) and PCV3, and to apply this method in the detection of PCV2 and PCV3. Primers specific to PCV2 and PCV3 were designed by reference to the respective gene sequences in GenBank. The reaction conditions of nano-dPCR were also optimized. An evaluation of the specificity and sensitivity of the established nano-dPCR protocol proved the method to be both specific and sensitive, with the lower detection limit for the amount of nucleic acid in PCV2 and PCV3 to be 93.2 and 91.6 copies/μL, respectively. This sensitivity was 100 times higher than that of conventional PCR. The method was applied to inspect 265 clinical samples sent for testing, and the results showed that PCV2 and PCV3 infection in pig was rather common, with 16.6% positive for PCV3, 14.7% positive for PCV2, and 6.8% for mixed infection. The detection results on clinical samples supported the newly established nano-dPCR method as a rapid and sensitive differential diagnosis for the early infection of PCV2 and PCV3.     

PCV2和PCV3双重纳米PCR方法的建立及初步应用

本研究旨在建立一种同时检测猪圆环病毒2型（PCV2）和猪圆环病毒3型（PCV3）的双重纳米PCR（nano-dPCR）方法,同时应用该方法对PCV2和PCV3进行检测。参考GenBank中登录的PCV2和PCV3型基因序列分别设计特异性引物,对nano-dPCR的反应条件进行优化;同时考察所建立的nano-dPCR检测方法的特异性和敏感性。结果显示,所建方法的特异性和敏感性良好,对PCV2和PCV3两种病毒的最低核酸检测量分别为93.2和91.6拷贝/μL,其敏感性比普通PCR高100倍。应用该方法对送检的265份临床样本进行检测,结果显示,PCV2和PCV3在猪群中存在普遍感染,PCV3和PCV2的阳性率分别为16.6%和14.7%,混合感染阳性率为6.8%。临床样品的检测结果表明,本试验建立的nano-dPCR方法为PCV2和PCV3早期感染进行快速、敏感鉴别诊断提供了新方法。     

猪圆环病毒Ⅱ型新疫苗可预防猪圆环病毒Ⅱ型相关疾病

美国堪萨斯州州立大学科学家完成了一项研究,结果表明新研制的猪圆环病毒Ⅱ型疫苗能有效预防猪圆环病毒Ⅱ型。病毒学家、诊断医学和病理学     

如何在田间评估PCV2疫苗的免疫效果

免疫控制猪圆环病毒2型(Porcine Circovirus 2,PCV2)有时被认为是一项不可思议的工作。然而,免疫预防成功的基础是科学。了解该过程的背景后,在求助于免疫接种时将有助于了解哪些结果是可以预测到的,哪些结果是无法预测到的。     

近十年来PCV2在英国的流行情况

10年前,仔猪断奶后多系统衰竭综合征(Post-Weaning Multisystemic Wasting Syndrome,PMWS)首次露面。自那时以来,养猪生产行业对猪圆环病毒2型(Porcine Circovirus type 2,PCV2)的认识已得到提高。回顾过去10年来PCV2在英国的流行情况,我们能够从中总结出怎样的发展趋势呢?     

Porcine reproductive and respiratory syndrome virus (PRRSV) influences infection dynamics of porcine circovirus type 2 (PCV2) subtypes PCV2a and PCV2b by prolonging PCV2 viremia and shedding

The objective of this study was to determine the effect of porcine reproductive and respiratory syndrome virus (PRRSV) infection on porcine circovirus type 2 (PCV2) subtypes a (PCV2a) or b (PCV2b) viremia and shedding characteristics in oral, nasal and fecal samples in experimentally infected pigs. Twenty-three, 2- to 6-week-old pigs were randomly divided into five groups: negative control (n=3), PCV2a-I (n=5), PCV2a-PRRSV-CoI (n=5), PCV2b-I (n=5), and PCV2b-PRRSV-CoI (n=5). Blood, oral, nasal and fecal swabs were collected in regular intervals from day post inoculation (dpi) 0 until dpi 70 and tested by quantitative real-time PCR for the presence and amount of PCV2 DNA and by ELISA for the presence of PCV2-specific antibodies. The results indicate that there were significantly (P<0.05) higher loads of PCV2a and PCV2b DNA in serum, oral swabs, nasal swabs and fecal swabs and a higher prevalence of detectable PCV2 antigen in tissues of pigs concurrently infected with PCV2 and PRRSV compared to pigs singularly infected with PCV2 further confirming that PRRSV enhances replication of PCV2. Moreover, PRRSV infection significantly prolonged the presence of PCV2 DNA in serum and increased the amount of PCV2 DNA in oral and nasal secretions and fecal excretions in the later stages of infection between dpi 28 and 70. Shedding patterns were similar between groups infected with PCV2a and PCV2b, indicating that there was no subtype-specific interaction with the PRRSV isolate used in this study. The results from this study highlight the interaction between PRRSV and PCV2 and the importance of controlling PRRSV infection in order to reduce PCV2 virus loads in pig populations.     

Porcine circovirus type 2 (PCV2) vaccination reduces PCV2 in a PCV2 and Salmonella enterica serovar Choleraesuis coinfection model

We previously reported that prior porcine circovirus type 2 (PCV2) infection potentiates the severity of clinical signs, lung lesions, and fecal shedding and tissue dissemination of Salmonella enterica serovar Choleraesuis in infected pigs. Here, we evaluated whether PCV2 vaccination is effective in reducing fecal shedding and tissue dissemination of S. Choleraesuis and improving clinical signs associated with PCV2 and S. Choleraesuis infection in 15 Cesarean-derived, colostrum-deprived pigs randomly assigned to 3 groups (n = 5/group). The vaccinated and co-infected (VAC-COINF) group received 2 ml of a commercial PCV2 vaccine at age 3 weeks. The VAC-COINF and co-infected (COINF) groups were inoculated intranasally with PCV2 and S. Choleraesuis at 5 and 7 weeks of age, respectively. The CONTROL group pigs received a similar volume of PBS for sham-vaccination and sham-inoculation. PCV2 vaccination clearly reduced PCV2 DNA load in the serum and postmortem tissue samples and decreased PCV2 antigen levels in tissue samples of the VAC-COINF group. After S. Choleraesuis infection, the incidence of several clinical signs increased in the VAC-COINF group compared to that in the COINF group. The microscopic lung lesions and weight gain, fecal shedding and tissue dissemination of S. Choleraesuis except in the spleen were not significantly different in the VAC-COINF and COINF groups. Thus, PCV2 vaccination reduced PCV2 in the S. Choleraesuis and PCV2 coinfection model and the effects on S. Choleraesuis were minimal.